Notice for trastuzumab deruxtecan (AstraZeneca Pty Ltd)
Active ingredients
trastuzumab deruxtecan
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
ENHERTU is indicated for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment
Therapeutic area
Oncology